Wall Street Zen cut shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) from a sell rating to a strong sell rating in a research report released on Saturday morning,Wall Street Zen reports.
CTNM has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Thursday, October 15th. Royal Bank Of Canada increased their price target on Contineum Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Robert W. Baird lowered Contineum Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $19.00 to $14.00 in a research report on Tuesday, October 13th. Morgan Stanley decreased their price objective on Contineum Therapeutics from $18.00 to $17.00 and set an “equal weight” rating for the company in a research note on Monday, September 28th. Finally, JonesTrading upped their price objective on Contineum Therapeutics from $24.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $21.40.
Read Our Latest Stock Analysis on Contineum Therapeutics
Contineum Therapeutics Price Performance
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). On average, sell-side analysts predict that Contineum Therapeutics will post -1.76 EPS for the current year.
Institutional Investors Weigh In On Contineum Therapeutics
Several large investors have recently made changes to their positions in the stock. Janus Henderson Group PLC lifted its position in Contineum Therapeutics by 11.7% in the 1st quarter. Janus Henderson Group PLC now owns 2,734,836 shares of the company’s stock valued at $35,594,000 after acquiring an additional 285,857 shares in the last quarter. HighVista Strategies LLC bought a new position in Contineum Therapeutics during the 3rd quarter worth about $2,923,000. Wellington Management Group LLP increased its holdings in Contineum Therapeutics by 171.2% during the 2nd quarter. Wellington Management Group LLP now owns 150,797 shares of the company’s stock worth $2,472,000 after purchasing an additional 95,188 shares in the last quarter. Eversept Partners LP raised its stake in shares of Contineum Therapeutics by 6.5% in the 1st quarter. Eversept Partners LP now owns 146,411 shares of the company’s stock valued at $1,912,000 after purchasing an additional 8,918 shares during the period. Finally, Seven Fleet Capital Management LP raised its stake in shares of Contineum Therapeutics by 123.8% in the 2nd quarter. Seven Fleet Capital Management LP now owns 60,541 shares of the company’s stock valued at $992,000 after purchasing an additional 33,487 shares during the period.
About Contineum Therapeutics
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological, inflammatory and fibrotic diseases. The company is based in San Diego, California, and was previously known as Pipeline Therapeutics. Its development programs include PIPE-307, an investigational M1 receptor antagonist being studied for neurological conditions, including relapsing-remitting multiple sclerosis. Contineum is also developing PIPE-791, an investigational LPA1 receptor antagonist for fibrotic lung diseases and related conditions.
Recommended Stories
- Five stocks we like better than Contineum Therapeutics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
